Healthcare Economist July 1, 2021
Cell and gene therapies have the potential to produce dramatic improvements in quality of life and survival for severe and often rare diseases. Currently, however, the cost of these treatments is high and access is sometimes limited. To identify some of these challenges in Europe EURODIS conducted an evaluation of country-specific challenges with respect to four criteria: assessment, affordability, availability and accessibility. These categories are defined as follows
- Assessment relates to the challenges of assessing the benefits and risks of a treatment (e.g., HTA);
- Affordability relates to pricing, funding and affordability;
- Availability relates to non-regulatory issues for making the product available particularly cross-border healthcare and hospital exemptions.
- Accessibility relates to high easy it is for patients to access the...
Today's Sponsors
Today's Sponsor